Skip to main content

Table 2 Change in absolute CST values from baseline to Week 12/EoT CIRC-values (FAS)

From: Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema

  ASP8232 (n = 32) ASP8232/ranibizumab (n = 32) Ranibizumab (n = 31)
Baseline, μm 535.8 (117.9) 511.8 (103.9) 501.6 (105.5)
Week 12 (EoT), μm 530.3 (127.4) 374.0 (105.6) 378.6 (107.5)
Change from baseline at EoT, μm − 5.5 (119.7) − 137.8 (142.5) − 123.1 (112.3)
  1. Data are presented as mean (SD)
  2. CIRC central imaging reading center, CST central subfield thickness, EoT end of treatment, FAS full analysis set